About this podcast:Recorded at the 2025 Immuno-Oncology 360º Summit, Stanford University's Dr Crystal Mackall shares work from her lab developing GD2-targeting CAR T cell therapy for the treatment of deadly pediatric brain tumor, as well as broader lessons on the evolution of cell therapy, and her forward-looking perspective on shaping the next generation of cancer treatments.
For more information, go to
IO360summit.com.